Legal status · United States
Is Degarelix legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Degarelix is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
Degarelix in the United States at a glance
| Classification | FDA-approved, prescription only |
|---|---|
| Note | NDA 022201, approved 24 December 2008, Ferring, marketed as Firmagon. The indication is advanced prostate cancer and nothing else. Subcutaneous injection only. |
| FDA approval status | FDA-approved on 24 December 2008 under NDA 022201, marketed as Firmagon, for treatment of patients with advanced prostate cancer. No boxed warning. Not approved for localised prostate cancer management outside that indication, for any use in women, or for any use in healthy adults. |
| Human studies cited | 3 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Degarelix profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Degarelix for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Degarelix is
A GnRH antagonist approved in 2008 for advanced prostate cancer. In its 610-patient phase 3, testosterone was at or below 0.5 ng/mL by day 3 in about 96 percent of degarelix patients and in none of the leuprolide patients, and it met non-inferiority over 12 months. Injection site reactions occurred in 40 percent versus under 1 percent with intramuscular leuprolide, and the trial designed to test whether it is safer for the heart was terminated early and found no difference.
Degarelix is a synthetic decapeptide containing five D-amino acids that blocks the GnRH receptor directly instead of overstimulating it. The FDA approved it on 24 December 2008 under NDA 022201 for treatment of patients with advanced prostate cancer.
Mechanism: Direct competitive antagonism at the pituitary GnRH receptor. Blocking the receptor stops luteinising hormone and follicle-stimulating hormone release immediately, so testosterone falls within days with no initial surge.
Regulatory history: FDA-approved on 24 December 2008 under NDA 022201, marketed as Firmagon, for treatment of patients with advanced prostate cancer. No boxed warning. Not approved for localised prostate cancer management outside that indication, for any use in women, or for any use in healthy adults.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Degarelix at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Degarelix in other countries
Frequently asked questions
Is Degarelix legal in the United States?
Yes. Degarelix is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: NDA 022201, approved 24 December 2008, Ferring, marketed as Firmagon. The indication is advanced prostate cancer and nothing else. Subcutaneous injection only.
Can I buy Degarelix in the United States?
Only with a prescription. Degarelix is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: NDA 022201, approved 24 December 2008, Ferring, marketed as Firmagon. The indication is advanced prostate cancer and nothing else. Subcutaneous injection only.
Is Degarelix FDA approved?
Yes. FDA status: FDA-approved on 24 December 2008 under NDA 022201, marketed as Firmagon, for treatment of patients with advanced prostate cancer. No boxed warning. Not approved for localised prostate cancer management outside that indication, for any use in women, or for any use in healthy adults.. Current US classification: "FDA-approved, prescription only". On the evidence, 3 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Degarelix live on its compound profile.
Degarelix profileThis page is general information about the regulatory status of Degarelix in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.